



Zoledronic Acid Use in the Day Hospice

Audit Design



Site of Primary Malignancy

- Retrospective
- Case note and drug chart review
- January 2011-December 2011 inclusive
- 24 patients identified from day hospice diary
- Final sample size was 19
- Up to 3 administrations were audited
- Documentation was assessed according to drug company and local guidelines



Indication

Results

Summary

Precautions before Administering Zoledronic Acid

- Just under half of patients had their allergy status documented
- No patients had a documented dental review before commencing treatment
- Only one patient had documentation of counselling regarding side effects of zoledronic acid
- The more treatments a patient received the less likely they were to have their bloods checked before administration

Prescribing


- Although documentation of zoledronic acid prescription was good, IV fluids, paracetamol, and calcium/vitamin D3 were unlikely to be prescribed
- 4 of the 19 patients received the incorrect dose for their renal function

Adverse Events


- The most likely adverse event was renal impairment
- Two patients developed hypocalcaemia but did not require treatment
- No patients were documented to have developed osteonecrosis of the jaw or experienced a drug interaction

Documentation of Reviews and Decision to Stop Treatment

- Of the 11 patients who received zoledronic acid for their bone pain 9 had the analgesic effect reviewed
- Frequently patients on zoledronic acid deteriorated and died so a clear decision to stop treatment was therefore not documented



Adverse Events



Prescribing

Interventions include a zoledronic acid notes proforma, a patient information leaflet, and staff education. The audit will be repeated.

Auditor: Dr A Sutherland, CMT 1
Supervisor : Dr C Hookey, Medical Director